Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 6/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | PRKACG | P22612 | 1/20 | 0.35 |
| ▸ | PRKACB | P22694 | 1/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14780330 | 0.88 | CDK2 (0.47) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL14780248 | 0.78 | CDK2 (0.48) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL14780256 | 0.73 | CDK2 (0.53) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL14780097 | 0.72 | CDK2 (0.52) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL14779070 | 0.70 | SLC29A1 (0.54) | — | |
| SCHEMBL14779909 | 0.70 | CDK2 (0.50) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL14779614 | 0.70 | CDK1 (0.52) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL14779332 | 0.70 | CDK2 (0.50) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL2027216 | 0.65 | CDK2 (0.63) | CDK1CCNB2CCNB1CCNB3CDK2 | |
| SCHEMBL14780251 | 0.65 | CDK2 (0.55) | CDK1CCNB2CCNB1CCNB3CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755977-B1 | 6,8-DISUBSTITUTED PURINE COMPOSITIONS AND THEIR PHARMACEUTICAL AND COSMETIC USE | Univerzita Palackého v Olomouci (CZ) | 2016-11-02 | — | — | EP | disclosed |
| US-20130072506-A1 | 6,8-DISUBSTITUTED PURINE COMPOSITIONS | ZAHAJSKA LENKA (CZ) | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072506-A1 | 6,8-DISUBSTITUTED PURINE COMPOSITIONS | UNG, PNP, UMPS | CDK1 624/4885CCNB2 388/4885CCNB1 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.